Concepedia

Author

Janet Dancey

National Cancer Institute

Also Known As

Cohen, Ezra W.E., Eng, Charis, J Dancey, J E Dancey, J. Dancey, J. E. Dancey, J.E. Dancey, Janet Dancey, Janet E Dancey, Janet E. Dancey

311

Publications

54.1K

Citations

81

H-Index

115

Concepts

All Affiliations

National Cancer InstitutePrincess Margaret Cancer CentreQueen's UniversityOntario Institute for Cancer ResearchThe University of Texas MD Anderson Cancer Center
JD

About

Janet Dancey is an author at National Cancer Institute specializing in oncology, medicine, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

14

15

29.5K

2

Engineering

4

4

223

3

Arts

1

1

113

4

Law

1

1

1.8K

5

Management

1

1

161

Janet Dancey

×

133

Publications

46.3K

Citations

71

H-Index

YearCitations

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts,

European Journal of Cancer

2008

28.6K

Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

Frances A. Shepherd, Janet Dancey, Rodryg Ramlau,

Journal of Clinical Oncology

2000

2.2K

RECIST 1.1—Update and clarification: From the RECIST committee

Lawrence H. Schwartz, Saskia Litière, Elisabeth G.E. de Vries,

European Journal of Cancer

2016

1.8K

Phase II Trial of Gefitinib in Recurrent Glioblastoma

Jeremy N. Rich, David A. Reardon, Terry Peery,

Journal of Clinical Oncology

2003

726

Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

Evanthia Galanis, Jan C. Buckner, Matthew J. Maurer,

Journal of Clinical Oncology

2005

690

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme

Susan M. Chang, Patrick Y. Wen, Timothy F. Cloughesy,

Investigational New Drugs

2005

400

Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Michael J. Moore, John Hamm, Janet Dancey,

Journal of Clinical Oncology

2003

396

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

Kamal S. Saini, Sherene Loi, Evandro de Azambuja,

Cancer Treatment Reviews

2013

370

Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

Amit M. Oza, Laurie Elit, Ming‐Sound Tsao,

Journal of Clinical Oncology

2011

333

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

Ignacio Durán, Jeremy Kortmansky, Deepti Singh,

British Journal of Cancer

2006

316

Page 1